G. Fronza

S. De Flora, F. D'Agostini, A. Izzotti, 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Heterogeneous p53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonal c‐myc and VDJ rearrangements

N. Chiorazzi, M. Ferrarini, A. Inga, 1997, International journal of cancer.

Nucleotide excision repair defect influences lethality and mutagenicity induced by Me-lex, a sequence-selective N3-adenine methylating agent in the absence of base excision repair.

P. Monti, G. Fronza, Y. Ciribilli, 2004, Biochemistry.

Defective nuclear localization of p53 protein in a Chinese hamster cell line is associated with the formation of stable cytoplasmic protein multimers in cells with gene amplification.

D. Lane, G. Fronza, P. Campomenosi, 2000, Carcinogenesis.

p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients.

A. Inga, P. Monti, G. Fronza, 2000, Mutagenesis.

Gambogic acid counteracts mutant p53 stability by inducing autophagy.

P. Degan, P. Monti, G. Fronza, 2017, Biochimica et biophysica acta. Molecular cell research.

NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome

R. Guigó, L. Baldini, A. Neri, 2020, Non-coding RNA.

Ultraviolet-light induced p53 mutational spectrum in yeast is indistinguishable from p53 mutations in human skin cancer.

A. Inga, P. Monti, G. Fronza, 1998, Carcinogenesis.

A gene trap approach to isolate mammalian genes involved in the cellular response to genotoxic stress.

G. Fronza, P. Menichini, L. Ottaggio, 1997, Nucleic acids research.

Analysis of stepwise genetic changes in an AIDS‐related Burkitt's lymphoma

N. Chiorazzi, M. Ferrarini, A. Inga, 2000, International journal of cancer.

Derivative chromosome 17 in a case of Burkitt lymphoma with 8;14 translocation.

G. Fronza, P. Campomenosi, L. Ottaggio, 1999, Cancer genetics and cytogenetics.

Determining mutational fingerprints at the human p53 locus with a yeast functional assay: a new tool for molecular epidemiology

M. Bolognesi, R. Iggo, A. Inga, 1997, Oncogene.

PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53.

G. Fronza, P. Menichini, L. Ottaggio, 2013, Biochimica et biophysica acta.

Extent of helix perturbation associated with DNA modification by the o-acetyl derivative of the carcinogen 4-hydroxyaminoquinoline-1-oxide.

S. Tornaletti, G. Fronza, P. Menichini, 1990, Biochimica et biophysica acta.

Rev1 and Polzeta influence toxicity and mutagenicity of Me-lex, a sequence selective N3-adenine methylating agent.

A. Inga, P. Monti, G. Fronza, 2008, DNA repair.

The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts.

A. Inga, P. Monti, G. Fronza, 2000, Mutation research.

Defective splicing induced by 4NQO in the hamster hprt gene.

A. Inga, G. Fronza, P. Campomenosi, 1994, Mutation research.

Stable formation of mutated p53 multimers in a Chinese hamster cell line causes defective p53 nuclear localization and abrogates its residual function

G. Fronza, P. Campomenosi, P. Menichini, 2006, Journal of cellular biochemistry.

Partial characterization of SUVi, a new mammalian gene induced by UV‐c and expressed during the S phase of the cell cycle

G. Fronza, P. Campomenosi, P. Menichini, 2001, Environmental and molecular mutagenesis.

Mutation spectra analysis suggests that N‐(2‐chloroethyl)‐N′‐cyclohexyl‐N‐nitrosourea‐induced lesions are subject to transcription‐coupled repair in Escherichia coli

A. Inga, G. Fronza, P. Menichini, 1997, Molecular carcinogenesis.

3-Methyl-3-deazaadenine, a stable isostere of N3-methyl-adenine, is efficiently bypassed by replication in vivo and by transcription in vitro.

S. Tornaletti, A. Inga, P. Monti, 2011, DNA repair.

p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements

R. Iggo, T. Crook, M. A. Resnick, 2001, Oncogene.

Comparison of the biological effects of MMS and Me-lex, a minor groove methylating agent: clarifying the role of N3-methyladenine.

A. Inga, P. Monti, G. Fronza, 2014, Mutation research.

Analysis of 4-nitroquinoline-1-oxide induced mutations at the hprt locus in mammalian cells: possible involvement of preferential DNA repair.

A. Inga, G. Fronza, P. Campomenosi, 1994, Mutagenesis.

The biological effects of N3‐methyladenine

G. Fronza, B. Gold, 2004, Journal of cellular biochemistry.

Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials

R. Foà, D. Rossi, G. Gaidano, 2021, American journal of hematology.

Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol

G. D’Arrigo, A. Neri, M. Ferrarini, 2021, European journal of haematology.

High frequency of genomic deletions induced by Me-lex, a sequence selective N3-adenine methylating agent, at the Hprt locus in Chinese hamster ovary cells.

A. Inga, P. Monti, G. Fronza, 2009, Mutation research.

Mutant p53K120R expression enables a partial capacity to modulate metabolism

P. Degan, P. Monti, G. Fronza, 2022, Frontiers in Genetics.

Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma

A. Izzotti, P. Monti, G. Fronza, 2021, Journal of personalized medicine.

Mutational fingerprint induced by the antineoplastic drug chloroethyl-cyclohexyl-nitrosourea in mammalian cells.

A. Inga, G. Fronza, P. Campomenosi, 1995, Cancer research.

MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells

M. Cilli, A. Neri, C. Tripodo, 2022, Blood advances.

Mutagenicity of N3-methyladenine: a multi-translesion polymerase affair.

A. Inga, P. Monti, G. Fronza, 2010, Mutation research.

The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study

A. Neri, M. Dono, M. Ferrarini, 2022, Hematological oncology.

Influences of Base Excision Repair Defects on the Lethality and Mutagenicity Induced by Me-lex, a Sequence-selective N3-Adenine Methylating Agent*

A. Inga, P. Monti, G. Fronza, 2002, The Journal of Biological Chemistry.

DNA adducts and chronic degenerative disease. Pathogenetic relevance and implications in preventive medicine.

J. Lewtas, S. De Flora, R. Balansky, 1996, Mutation research.

Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.

A. Inga, G. Fronza, Y. Ciribilli, 2007, Mutagenesis.

DNA damage and cytotoxicity induced by minor groove binding methyl sulfonate esters.

G. Fronza, B. Gold, S. Varadarajan, 2003, Biochemistry.

Evidence in Escherichia coli that N3-methyladenine lesions induced by a minor groove binding methyl sulfonate ester can be processed by both base and nucleotide excision repair.

G. Fronza, B. Gold, Y. Zhang, 2001, Biochemistry.

The kinetics of p53‐binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage

A. Inga, G. Fronza, P. Menichini, 2007, Journal of cellular biochemistry.

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis

Thierry Soussi, Bernard Leroy, Jean Louis Fournier, 2012, Nucleic Acids Res..

p53 Mutations and DNA Ploidy in Colorectal Adenocarcinomas

R. Orecchia, G. Fronza, P. Campomenosi, 1998, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

TP53 Mutants in the Tower of Babel of Cancer Progression

A. Inga, P. Monti, G. Fronza, 2014, Human mutation.

Dominant-Negative Features of Mutant TP53 in Germline Carriers Have Limited Impact on Cancer Outcomes

A. Inga, P. Monti, G. Fronza, 2011, Molecular Cancer Research.

limited impact on cancer outcomes.

A. Inga, P. Monti, G. Fronza, 2011 .

Cancer Genes and Genomics Dominant-Negative Features of Mutant TP 53 in Germline Carriers Have Limited Impact on Cancer Outcomes

A. Inga, P. Monti, G. Fronza, 2011 .

Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay

P. Hainaut, P. Monti, G. Fronza, 2001, Oncogene.

The TP 53 website : an integrative resource centre for the TP 53 mutation database and TP 53 mutant analysis

Jean Louis Fournier, C. Ishioka, T. Soussi, 2012 .

P63 modulates the expression of the WDFY2 gene which is implicated in cancer regulation and limb development

A. Inga, P. Monti, G. Fronza, 2019, Bioscience reports.

Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules.

L. Saraíva, P. Monti, G. Fronza, 2015, Experimental cell research.

MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma

S. Parodi, G. Tonini, A. Inga, 2010, Pediatric blood & cancer.

MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma

S. Parodi, G. Tonini, A. Inga, 2009, Pediatric blood & cancer.

Characterization of the p53 mutants ability to inhibit p73β transactivation using a yeast-based functional assay

A. Inga, P. Monti, G. Fronza, 2003, Oncogene.

Evaluating the Influence of a G-Quadruplex Prone Sequence on the Transactivation Potential by Wild-Type and/or Mutant P53 Family Proteins through a Yeast-Based Functional Assay

A. Inga, P. Monti, G. Fronza, 2021, Genes.

Chromosomal aberrations evaluated by CGH, FISH and GTG-banding in a case of AIDS-related Burkitt's lymphoma.

G. Fronza, L. Ottaggio, S. Viaggi, 2000, Haematologica.

p53 is frequently mutated in Barrett's metaplasia of the intestinal type.

A. Inga, P. Monti, G. Fronza, 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Lack of mutations in K-ras codons 12 and 13 in human atherosclerotic lesions.

S. De Flora, A. Izzotti, G. Fronza, 1996, Chemico-biological interactions.

Effect of N3-Methyladenine and an Isosteric Stable Analogue on DNA Polymerization

G. Fronza, B. Gold, Ruo-wen Wang, 2010, Journal of nucleic acids.

XRCC1 deficiency influences the cytotoxicity and the genomic instability induced by Me-lex, a specific inducer of N3-methyladenine.

A. Inga, P. Monti, G. Fronza, 2010, DNA repair.

Relationship between DNA Methylation and Mutational Patterns Induced by a Sequence Selective Minor Groove Methylating Agent*

A. Inga, P. Monti, G. Fronza, 1999, The Journal of Biological Chemistry.

EEC‐ and ADULT‐Associated TP63 Mutations Exhibit Functional Heterogeneity Toward P63 Responsive Sequences

R. Ravazzolo, A. Inga, P. Monti, 2013, Human mutation.

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

A. Neri, M. Ferrarini, P. Monti, 2020, Frontiers in Oncology.

Increased Risk of Colorectal Adenomas in Italian Subjects Carrying the p53 PIN3 A2-Pro72 Haplotype

A. Inga, G. Fronza, P. Menichini, 2007, Digestion.

PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.

A. Inga, G. Fronza, P. Menichini, 2010, Biochemical and biophysical research communications.

PRIMA‐1 synergizes with adriamycin to induce cell death in non‐small cell lung cancer cells

A. Inga, G. Fronza, P. Menichini, 2008, Journal of cellular biochemistry.

DNA Topoisomerase I and Poly(ADP-Ribose) Polymerase in the Early Stages of Hepatocarcinogenesis

G. Fronza, A. Abbondandolo, P. Giannoni, 1992 .

Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code

D. Menendez, A. Inga, P. Monti, 2013, Nucleic acids research.

Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival

P. Degan, P. Monti, G. Fronza, 2019, Bioscience reports.

Involvement of human p53 in induced intrachromosomal recombination in Saccharomyces cerevisiae.

G. Fronza, A. Galli, M. Simili, 2004, Mutagenesis.

Involvement of human p 53 in induced intrachromosomal recombination in Saccharomyces cerevisiae

G. Fronza, A. Galli, M. Simili, 2004 .

Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma.

S. Parodi, G. Tonini, A. Inga, 2008, European journal of cancer.

Tumour p53 mutations exhibit promoter selective dominance over wild type p53

A. Inga, P. Monti, G. Fronza, 2002, Oncogene.

Study on aneuploidy and p53 mutations in astrocytomas.

S. Bonassi, R. Pisani, A. Inga, 1996, Cancer genetics and cytogenetics.

The CDKN2A/p16INK4a 5′UTR sequence and translational regulation: impact of novel variants predisposing to melanoma

P. Queirolo, R. Spitale, A. Inga, 2016, Pigment cell & melanoma research.

The ultimate carcinogen of 4-nitroquinoline 1-oxide does not react with Z-DNA and hyperreacts with B-Z junctions.

S. Tornaletti, G. Fronza, C. Rodolfo, 1994, Nucleic acids research.

Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation

A. Izzotti, P. Monti, G. Fronza, 2018, Scientific Reports.

TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors

A. Neri, M. Dono, M. Ferrarini, 2020, Expert opinion on investigational drugs.

TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia

D. Rossi, G. Fronza, A. Schuh, 2021, Clinical Cancer Research.

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia

E. Montserrat, R. Foà, D. Rossi, 2021, Frontiers in Oncology.

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

A. Neri, M. Ferrarini, P. Monti, 2021, Cells.

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

R. Foà, D. Rossi, G. Gaidano, 2021, American journal of hematology.

Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

A. Neri, M. Dono, M. Ferrarini, 2020, Scientific Reports.

TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear

A. Izzotti, P. Queirolo, P. Monti, 2017, Oncology reports.

Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

R. Foà, D. Rossi, G. Gaidano, 2021, American journal of hematology.

Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases

R. Foà, D. Rossi, G. Gaidano, 2020, European journal of haematology.

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

R. Foà, G. Fronza, A. Cuneo, 2023, Leukemia.

In vitro DNA modification by the ultimate carcinogen of 4-nitroquinoline-1-oxide: influence of superhelicity.

S. Tornaletti, G. Fronza, P. Menichini, 1989, Carcinogenesis.

Perturbation of DNA tertiary structure by physical and chemical carcinogens: effects on DNA repair processes.

S. Tornaletti, G. Fronza, P. Menichini, 1989, Annali dell'Istituto Superiore di Sanità.

Concentration-dependent mutational hotspots induced by the antineoplastic drug chloroethyl-cyclohexyl-nitroso-urea in mammalian cells.

A. Inga, G. Fronza, A. Abbondandolo, 1996, Mutation research.

Mutation spectrum of 4-nitroquinoline 1-oxide-damaged single-stranded shuttle vector DNA transfected into monkey cells.

A. Inga, G. Fronza, P. Campomenosi, 1994, Mutation research.

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

R. Foà, G. Gaidano, G. D’Arrigo, 2020, Blood Cancer Journal.

DNA Unwinding: Common Modification Induced by “Bulky Adducts” to DNA Structure

S. Tornaletti, G. Fronza, P. Menichini, 1989 .

Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype

L. Luzzatto, J. Jordan, A. Inga, 2007, Clinical Cancer Research.

p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-Based Screening System

J. Jordan, A. Inga, P. Monti, 2011, PloS one.

Multiple mutations and frameshifts are the hallmark of defective hPMS2 in pZ189-transfected human tumor cells

Gilberto Fronza, Margherita Bignami, Sabrina Ceccotti, 2000, Nucleic Acids Res..

SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.

Daniel F. A. R. Dourado, Maria M. M. Santos, A. Gomes, 2020, Biochimica et biophysica acta. General subjects.

Structural studies on mechanisms to activate mutant p53.

A. Inga, G. Fronza, H. Viadiu, 2014, Sub-cellular biochemistry.

Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines.

A. Albini, A. Ardizzoni, G. Fronza, 1997, International Journal of Oncology.

The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

D. Rossi, G. Gaidano, A. Neri, 2023, American journal of hematology.

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers

G. Fronza, P. Menichini, S. Mammoliti, 2023, Frontiers in Immunology.

Mutational Fingerprint Induced by the Antineoplastic Drug Chioroethylcyclohexyl Chioroethylcyclohexyl Chioroethylcyclohexyl nitrosourea in Mammalian Cells '

A. Inga, G. Fronza, P. Campomenosi, 2022 .

Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival

P. Degan, P. Monti, G. Fronza, 2019, Bioscience reports.

ΔN-P63α and TA-P63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites

A. Inga, P. Monti, G. Fronza, 2014, Oncotarget.